JP2006501181A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501181A5
JP2006501181A5 JP2004518651A JP2004518651A JP2006501181A5 JP 2006501181 A5 JP2006501181 A5 JP 2006501181A5 JP 2004518651 A JP2004518651 A JP 2004518651A JP 2004518651 A JP2004518651 A JP 2004518651A JP 2006501181 A5 JP2006501181 A5 JP 2006501181A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004518651A
Other languages
English (en)
Japanese (ja)
Other versions
JP4541882B2 (ja
JP2006501181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/007005 external-priority patent/WO2004005248A1/en
Publication of JP2006501181A publication Critical patent/JP2006501181A/ja
Publication of JP2006501181A5 publication Critical patent/JP2006501181A5/ja
Application granted granted Critical
Publication of JP4541882B2 publication Critical patent/JP4541882B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004518651A 2002-07-02 2003-07-01 Smacタンパク質のアポトーシスタンパク質阻害物質(iap)との結合に対するペプチド阻害剤 Expired - Fee Related JP4541882B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39315002P 2002-07-02 2002-07-02
PCT/EP2003/007005 WO2004005248A1 (en) 2002-07-02 2003-07-01 Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Publications (3)

Publication Number Publication Date
JP2006501181A JP2006501181A (ja) 2006-01-12
JP2006501181A5 true JP2006501181A5 (cg-RX-API-DMAC10.html) 2006-08-31
JP4541882B2 JP4541882B2 (ja) 2010-09-08

Family

ID=30115550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518651A Expired - Fee Related JP4541882B2 (ja) 2002-07-02 2003-07-01 Smacタンパク質のアポトーシスタンパク質阻害物質(iap)との結合に対するペプチド阻害剤

Country Status (8)

Country Link
US (2) US20060128632A1 (cg-RX-API-DMAC10.html)
EP (1) EP1519918A1 (cg-RX-API-DMAC10.html)
JP (1) JP4541882B2 (cg-RX-API-DMAC10.html)
CN (1) CN100384819C (cg-RX-API-DMAC10.html)
AU (1) AU2003249920A1 (cg-RX-API-DMAC10.html)
BR (1) BR0312408A (cg-RX-API-DMAC10.html)
CA (1) CA2491041A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004005248A1 (cg-RX-API-DMAC10.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CN1933847A (zh) * 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
AU2005210137B2 (en) * 2004-02-05 2009-06-04 Novartis Ag Combination of (a) a DNA topoisomerase inhibitor and (b) an IAP inhibitor
EP1740173A4 (en) * 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
SG152225A1 (en) * 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
RS53734B1 (sr) 2004-07-02 2015-06-30 Genentech Inc. Inhibitori iap
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Iap結合性化合物
KR20120127754A (ko) * 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
US7517906B2 (en) * 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US8318717B2 (en) 2005-05-25 2012-11-27 2Curex Compounds modifying apoptosis
EP1888619B1 (en) 2005-05-25 2013-04-17 2cureX ApS Compounds modifying apoptosis
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
BRPI0617751A2 (pt) * 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
US8247557B2 (en) * 2005-12-19 2012-08-21 Genentech, Inc. IAP inhibitors
RU2008129630A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Комбинация органических соединений
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
EP2024362A4 (en) * 2006-05-16 2012-01-25 Pharmascience Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0715195A2 (pt) * 2006-07-24 2013-06-11 Tetralogic Pharm Corp composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AU2007307763A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
KR20090087094A (ko) 2006-11-28 2009-08-14 노파르티스 아게 Iap 억제제 및 flt3 억제제의 조합물
BRPI0719481A2 (pt) * 2006-12-19 2014-02-11 Genentech Inc " composto, método de indução de apoptose em uma célula, de sensibilização de uma célula, para inibir a ligação de uma proteína iap a uma proteína caspase, para tratar uma doença ou condição associada com a superexpressão de uma proteína iap e para tratar câncer"
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
NZ580313A (en) * 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
RU2491276C2 (ru) 2007-04-30 2013-08-27 Дженентек, Инк. Ингибиторы iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
RU2010133548A (ru) * 2008-01-11 2012-02-20 Дженентек, Инк. (Us) Ингибиторы iap
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
CN105646471A (zh) 2009-08-12 2016-06-08 诺华股份有限公司 细胞凋亡蛋白抑制剂的固体口服制剂和晶形
EP2478358A1 (en) * 2009-09-18 2012-07-25 Novartis AG Biomarkers for iap inhibitor compounds
CN102050867A (zh) * 2009-11-10 2011-05-11 上海艾力斯医药科技有限公司 四肽类似物、制备方法及其应用
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
CA2988436A1 (en) * 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
KR102570992B1 (ko) 2016-11-01 2023-08-28 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
CN110291087B (zh) 2016-12-01 2024-07-09 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
CA3070992A1 (en) * 2017-07-25 2019-01-31 Hepagene Therapeutics, Inc. Dimeric peptide inhibitors of apoptosis proteins
WO2019021289A1 (en) * 2017-07-27 2019-01-31 The National Institute for Biotechnology in the Negev Ltd. SMAC / DIABLO INHIBITORS USEFUL IN THE TREATMENT OF CANCER
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN112218859B (zh) 2018-04-04 2024-10-29 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
IL322247A (en) 2023-01-26 2025-09-01 Arvinas Operations Inc Cerebellon-based KRAS-disrupting proteins and related uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US6881825B1 (en) * 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten

Similar Documents

Publication Publication Date Title
JP2006501181A5 (cg-RX-API-DMAC10.html)
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
ME00876B (me) 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati
ATE126216T1 (de) Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
IL51297A (en) Proline derivatives and related compounds pharmaceutical compositions containing the same and process for the preparation thereof
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
SE7614258L (sv) Forfarande for framstellning av kinazoloderivat
NO156690C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater.
BR8202861A (pt) Composto composicao farmaceutica processo para baixar a pressao sanguinea de seres humanos processo para preparar um composto e process para preparar uma composicao farmaceutica
SE9703377D0 (sv) New compounds
PT992509E (pt) Novos derivados macrolidos
DE60105610D1 (en) Pyrazinonderivate
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
KR940011450A (ko) 살진균성 2-알콕시-2-이미다졸린-5-온 유도체
RU2004102398A (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
SE8007025L (sv) Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem
RU2001104880A (ru) Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции
NO150316C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nitrosoureaderivater
FR2793246B1 (fr) Nouveaux derives de 1-aza-2-alkyl-6-aryl-cycloalcanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
SE8500964L (sv) Aminodiarylsulfoxidderivat, forfarande for framstellning derav och farmaceutiska och pesticidiska kompositioner innehallande desamma
RU2005124286A (ru) Производное олигосахаридов
JP2008543941A (ja) アンサマイシン製剤およびその使用方法